A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
Launched by ALNYLAM PHARMACEUTICALS · May 20, 2024
Trial Information
Current as of February 19, 2025
Active, not recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must have been born in Japan, and their biological parents and grandparents must have been of Japanese origin
- • Has mean systolic office blood pressure (SBP) of \>130 and \<=165 mmHg by automated office blood pressure measurement, after a minimum of 3 weeks of washout if taking hypertensive medication
- • Has 24-hour mean SBP ≥130 mmHg by ambulatory blood pressure monitoring (ABPM), without antihypertensive medication
- Exclusion Criteria:
- • Has secondary hypertension, symptomatic orthostatic hypotension
- • Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2× upper limit of normal (ULN)
- • Has elevated serum potassium \>5 mmol/L
- • Has estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m\^2
- • Has received an investigational agent within the last 30 days
- • Has Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus or newly diagnosed Type 2 diabetes mellitus
- • Has history of intolerance to SC injection(s)
Trial Officials
Medical Director
Study Director
Alnylam Pharmaceuticals
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a pioneering biopharmaceutical company focused on the development of innovative therapies based on RNA interference (RNAi) technology. Founded in 2002, Alnylam is dedicated to transforming the treatment landscape for patients with genetically defined diseases by leveraging its proprietary platform to discover and develop novel therapeutics. With a robust pipeline of clinical programs targeting a range of conditions, including rare genetic disorders and prevalent diseases, Alnylam is committed to advancing scientific research and improving patient outcomes through cutting-edge medicine and rigorous clinical trials. The company emphasizes collaboration and transparency in its operations, fostering partnerships within the scientific community to drive innovation and enhance healthcare solutions globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fukuoka, , Japan
Tokyo, , Japan
Osaka, , Japan
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0